Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNPCurrent treatment ...
Rhinitis VA Rating: What is the VA rating for chronic rhinitis?
Allergic rhinitis is a common issue that many veterans experience, primarily triggered by allergens such as dust, pollen, or ...
Hosted on MSN2d
First Drug OK'd for Chronic Rhinosinusitis With Nasal Polyps in Adolescents
The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...
Hosted on MSN16d
Neffy Is About to Hit Shelves: Considerations for Prescribing
In addition, people will need to discuss with their doctor whether they can use the epinephrine nasal spray if they have a ...
7 Top Gene-Editing Stocks to Buy
Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $29.9 billion by 2032, ...
Rolling Out7d
5 natural remedies to relieve nasal and throat allergies
If you’ve ever woken up with a stuffy nose, scratchy throat, and watery eyes, you know how disruptive nasal and throat allergies can be. These allergies, ...
PipelineReview.com7d
Depemokimab late-breaking data presented at ERS show a 54% reduction in severe asthma exacerbations
LONDON, UK I 09, 2024 I GSK plc (LSE/NYSE: GSK) today presented the full results from the SWIFT-1 and SWIFT-2 phase III clinical trials which ...
WebMD13d
New Needle-Free Epinephrine Nasal Spray a ‘Game Changer’
The FDA has approved a nasal spray, called neffy, to treat serious allergic reactions in adults and children who weigh at ...
Entrepreneur1d
3 Genomics Stocks Transforming Healthcare
On September 13, the U.S. Food and Drug Administration (FDA) approved the use of Dupixent® (dupilumab) as an add-on maintenance treatment for adolescent patients aged 12 to 17 years with inadequately ...